Answers are grounded in this paper and cite their sources.
Case report shows improvement in symptoms of chronic GVHD, suggesting possible extended use.
In long‐standing fibrotic chronic GVHD refractory to multiple systemic therapies, belumosudil may provide clinically meaningful patient‐reported improvement and reduce infection‐related hospitalizations even when early NIH organ scores remain stable. When benefits are evident and safety is acceptable, continuation beyond 3–6 months may be reasonable.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: